Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Sanofi-Aventis and its Sanofi Pasteur vaccines division will work with the German biotech firm Pieris. The goal is to develop drug candidates from Pieris’ library of low-molecular-weight proteins, called anticalins, against at least two disease targets. Sanofi will pay $4.8 million up front, as well as provide R&D funding and milestone payments. For each resulting product, Pieris could receive up to $60 million. Separately, Sanofi Pasteur will acquire Orlando, Fla.-based VaxDesign for $55 million. Initially supported by government defense funding, VaxDesign has developed in vitro models of the human immune system that can be used instead of animal models.
This article has been sent to the following recipient: